VBL Therapeutics to Report First Quarter 2017 Results on May 15
03 May 2017 - 10:00PM
VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology
company focused on the discovery, development and commercialization
of first-in-class treatments for cancer, today announced that it
will host a conference call and live audio webcast on Monday, May
15, 2017 at 8:30am Eastern Time to report first quarter ended March
31, 2017 financial results.
Monday, May 15th @ 8:30am Eastern Time
Domestic: |
866-409-1555 |
International:
|
913-661-9178 |
Conference ID:
|
7109868 |
Webcast: |
http://edge.media-server.com/m/p/hg84w5hv |
|
|
Replays,
available through May 29, 2017: |
Toll Free: |
844-512-2921 |
International: |
412-317-6671 |
Conference ID: |
7109868 |
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of first-in-class treatments for
cancer. The Company’s lead oncology product candidate, ofranergene
obadenovec (VB-111), is a first-in-class biologic agent that uses a
dual mechanism to target solid tumors. It utilizes an
angiogenesis-specific sensor (VBL's PPE-1-3x proprietary promoter)
to specifically target the tumor vasculature, by induction of cell
death in angiogenic endothelial cells in the tumor milieu.
Moreover, it is an immune-stimulant that triggers a local
anti-tumor immune response, which is accompanied by recruitment of
CD8 T-cells and apoptosis of tumor cells. Ofranergene obadenovec is
positioned to treat a wide range of solid tumors and is
conveniently administered as an IV infusion once every two months.
It has been observed to be well-tolerated in >200 cancer
patients and we have observed its efficacy signals in an “all
comers” Phase 1 trial as well as in three tumor-specific Phase 2
studies. Ofranergene obadenovec is currently being studied in a
Phase 3 pivotal trial for recurrent Glioblastoma, conducted under
an FDA Special Protocol Assessment (SPA).
INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
(646) 597-6979
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2024 to May 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From May 2023 to May 2024